MarketPeel
Insider Trading Intelligence
NS

Nicholas A. Saccomano

OKUR
PRESIDENT AND CEO · ONKURE THERAPEUTICS, INC. · CIK 0001609284
FILING MIX · LIFETIME53%/47%
BUYS
8
SELLS
7
TOTAL VALUE
$4.0K
COMPANIES
1
ACTIVE SINCE
Oct 2024
HOLDINGS NOW
11,247
AVG SELL PX
$3.06
TRADE KIND
SHOWING 15 / 15
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
6 backtested trades · 8 horizons · 10 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Nicholas A. Saccomano, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d6+83.33%-3.30%+1.98%-5.28%-6.14%
14d6+66.67%-0.97%+1.86%-2.83%-3.86%
30d6+66.67%-2.95%+6.20%-9.15%-5.19%
60d6+66.67%-2.41%+8.76%-12.11%-12.83%
90d6+33.33%+3.69%+11.71%-8.03%-2.10%
180d6(1 pending)+40.00%+21.96%+16.93%+5.02%+11.49%
1y6(3 pending)+0.00%+53.93%+28.18%+25.75%+8.14%
2y6(6 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
OKUR · 11,247 shares · as of Jun 22, 2026
0135,558271,116406,674542,23220252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2024
2025
2025
2025
2025
2026
2026
FLOW · 8 buys / 7 sellsCOVERAGE · 7 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
OKUR
ONKURE THERAPEUTICS, INC.
SALE
President and CEO
86$4.40$37811,247Jun 22, 2026Jun 24, 2026View →
OKUR
ONKURE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
330,000330,000Apr 1, 2026Apr 3, 2026View →
OKUR
ONKURE THERAPEUTICS, INC.
SALE
President and CEO
86$4.16$3577,333Mar 23, 2026Mar 24, 2026View →
OKUR
ONKURE THERAPEUTICS, INC.
SALE
President and CEO
87$2.97$2587,419Dec 22, 2025Dec 23, 2025View →
OKUR
ONKURE THERAPEUTICS, INC.
SALE
President and CEO
88$2.62$2313,506Sep 22, 2025Sep 24, 2025View →
OKUR
ONKURE THERAPEUTICS, INC.
SALE
President and CEO
88$2.38$2103,594Jun 23, 2025Jun 25, 2025View →
OKUR
ONKURE THERAPEUTICS, INC.
SALE
President and CEO
516$2.67$1.4K3,682Apr 7, 2025Apr 8, 2025View →
OKUR
ONKURE THERAPEUTICS, INC.
SALE
President and CEO
358$3.33$1.2K4,198Apr 4, 2025Apr 8, 2025View →
OKUR
ONKURE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
130,000130,000Jan 27, 2025Jan 29, 2025View →
OKUR
ONKURE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
8,4498,449Oct 4, 2024Oct 8, 2024View →
OKUR
ONKURE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
4,5564,556Oct 4, 2024Oct 8, 2024View →
OKUR
ONKURE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
2,3592,359Oct 4, 2024Oct 8, 2024View →
OKUR
ONKURE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
16,89816,898Oct 4, 2024Oct 8, 2024View →
OKUR
ONKURE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
1,4851,485Oct 4, 2024Oct 8, 2024View →
OKUR
ONKURE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
542,232542,232Oct 4, 2024Oct 8, 2024View →
Other insiders · OKUR
Loading peer insiders…
About this filer
CIK 0001609284
ROLE
President and CEO
PRIMARY
OKUR
COMPANIES
1
ACTIVE SINCE
Oct 2024
MARKETPEEL · /INSIDER/0001609284DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback